Approval of generic Dostinex

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Jul 10 2007

Barr Pharmaceuticals, Inc. has announced that its subsidiary Barr Laboratories, Inc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Pharmacia and Upjohn Company's Dostinex (cabergoline) tablets, 0.5 mg.

The Company's Abbreviated New Drug Application (ANDA) was acquired from Teva Pharmaceuticals Industries Ltd. in connection with the acquisition of Ivax by Teva in January 2006. The Company plans to launch a product that is supplied by Teva in September 2007.

Dostinex had annual sales of approximately $68 million for the twelve months ended May 2007, based on IMS sales data.

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Source:

http://www.barrlabs.com/

Posted in: Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

How can food influence the severity of menopausal hot flashes?
Can you spot the difference? Study explores the appeal of AI-generated vs. real food images
Feeling lonely? It may affect how your brain reacts to food, new research suggests
Ultra-processed foods raise chronic kidney disease risk, study shows
Study exposes food insecurity among graduate students and postdocs
New research sheds light on how GLP-1 obesity drugs may change food cravings
Renaissance of "food as medicine" in modern clinical trials
Study links ultra-processed food consumption with higher cardiovascular risk

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Maternal influences on food allergy prevention: A closer look at diet and environment